These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: Tan S; Day D; Nicholls SJ; Segelov E JACC CardioOncol; 2022 Dec; 4(5):579-597. PubMed ID: 36636451 [TBL] [Abstract][Full Text] [Related]
3. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition. Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B Front Immunol; 2020; 11():624547. PubMed ID: 33552089 [TBL] [Abstract][Full Text] [Related]
4. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A Front Immunol; 2022; 13():779691. PubMed ID: 35558065 [TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies. Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H Front Oncol; 2022; 12():934093. PubMed ID: 35912183 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors. Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159 [TBL] [Abstract][Full Text] [Related]
13. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161 [TBL] [Abstract][Full Text] [Related]
14. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759 [TBL] [Abstract][Full Text] [Related]
15. An Increased Understanding of the Association Between Atherosclerosis and Immune Checkpoint Inhibitors. Ellison JM; Nohria A Curr Cardiol Rep; 2023 Aug; 25(8):879-887. PubMed ID: 37395892 [TBL] [Abstract][Full Text] [Related]
16. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858 [TBL] [Abstract][Full Text] [Related]
17. B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications. Pattarabanjird T; Li C; McNamara C JACC Basic Transl Sci; 2021 Jun; 6(6):546-563. PubMed ID: 34222726 [TBL] [Abstract][Full Text] [Related]
18. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. Yao L; Jia G; Lu L; Bao Y; Ma W Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388 [TBL] [Abstract][Full Text] [Related]
19. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. El Osta B; Hu F; Sadek R; Chintalapally R; Tang SC Crit Rev Oncol Hematol; 2017 Nov; 119():1-12. PubMed ID: 29065979 [TBL] [Abstract][Full Text] [Related]
20. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]